Literature DB >> 23710689

The association between serological and dietary vitamin D levels and hepatitis C-related liver disease risk differs in African American and white males.

D L White1, S Tavakoli-Tabasi, F Kanwal, D J Ramsey, A Hashmi, J Kuzniarek, P Patel, J Francis, H B El-Serag.   

Abstract

BACKGROUND: Vitamin D may affect the severity of HCV-related liver disease. AIM: To examine the association between serum vitamin D levels and advanced liver disease in a multiethnic US cohort of HCV patients, and account for dietary and supplemental intake.
METHODS: We measured serum 25-hydroxyvitamin D levels and used FibroSURE-ActiTest to assess hepatic pathology in a cohort of HCV-infected male veterans. We estimated and adjusted for daily intake of vitamin D from diet using a Dietary History Questionnaire, and dispensed prescriptions prior to study enrolment. We used race-stratified logistic regression analyses to evaluate the relationship between serum vitamin D levels and risk of advanced fibrosis (F3/F4-F4) and advanced inflammation (A2/A3-A3).
RESULTS: A total of 163 African American (AA) and 126 White non-Hispanics were studied. Overall, ~44% of AAs and 15% of Whites were vitamin D deficient (<12 ng/mL) or insufficient (12-19 ng/mL); 4% of AAs and 9% of White patients had an elevated level (>50 ng/mL). Among AAs, patients with elevated serum vitamin D levels had significantly higher odds of advanced fibrosis (OR = 12.91, P = 0.03) than those with normal levels. In contrast, AAs with insufficient or deficient levels had > two-fold excess risk of advanced inflammation (P = 0.06). Among White males there was no association between vitamin D levels and advanced fibrosis (F3/F4-F4) or inflammation (A2/A3-A3) risk.
CONCLUSIONS: We observed potential differences in the association between vitamin D levels and degree of HCV-related hepatic fibrosis between White and African American males. Additional research is necessary to confirm that high serum vitamin D levels may be associated with advanced fibrosis risk in African American males, and to evaluate whether racial differences exist in HCV-infected females. © Published 2013. This article is a US Government work and is in the public domain in the USA.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23710689      PMCID: PMC3742078          DOI: 10.1111/apt.12341

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  27 in total

1.  Vitamin D supplementation improves response to antiviral treatment for recurrent hepatitis C.

Authors:  Davide Bitetto; Carlo Fabris; Ezio Fornasiere; Corrado Pipan; Elisa Fumolo; Annarosa Cussigh; Sara Bignulin; Sara Cmet; Elisabetta Fontanini; Edmondo Falleti; Romina Martinella; Mario Pirisi; Pierluigi Toniutto
Journal:  Transpl Int       Date:  2011-01       Impact factor: 3.782

2.  Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response.

Authors:  Philip T Liu; Steffen Stenger; Huiying Li; Linda Wenzel; Belinda H Tan; Stephan R Krutzik; Maria Teresa Ochoa; Jürgen Schauber; Kent Wu; Christoph Meinken; Diane L Kamen; Manfred Wagner; Robert Bals; Andreas Steinmeyer; Ulrich Zügel; Richard L Gallo; David Eisenberg; Martin Hewison; Bruce W Hollis; John S Adams; Barry R Bloom; Robert L Modlin
Journal:  Science       Date:  2006-02-23       Impact factor: 47.728

3.  A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C.

Authors:  Yen Ngo; Mona Munteanu; Djamila Messous; Frederic Charlotte; Françoise Imbert-Bismut; Dominique Thabut; Pascal Lebray; Vincent Thibault; Yves Benhamou; Joseph Moussalli; Vlad Ratziu; Thierry Poynard
Journal:  Clin Chem       Date:  2006-08-24       Impact factor: 8.327

4.  Vitamin D2 is much less effective than vitamin D3 in humans.

Authors:  Laura A G Armas; Bruce W Hollis; Robert P Heaney
Journal:  J Clin Endocrinol Metab       Date:  2004-11       Impact factor: 5.958

5.  Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C.

Authors:  Salvatore Petta; Calogero Cammà; Concetta Scazzone; Claudio Tripodo; Vito Di Marco; Antonino Bono; Daniela Cabibi; Giusalba Licata; Rossana Porcasi; Giulio Marchesini; Antonio Craxí
Journal:  Hepatology       Date:  2010-04       Impact factor: 17.425

6.  Fibrotest-Actitest: the biochemical marker of liver fibrosis--the Israeli experience.

Authors:  Gilles Morali; Yaacov Maor; Rachel Klar; Marius Braun; Ziv Ben Ari; Yoram Bujanover; Eli Zuckerman; Sarah Boger; Philippe Halfon
Journal:  Isr Med Assoc J       Date:  2007-08       Impact factor: 0.892

7.  Novel biomarkers predict liver fibrosis in hepatitis C patients: alpha 2 macroglobulin, vitamin D binding protein and apolipoprotein AI.

Authors:  Ai-Sheng Ho; Chun-Chia Cheng; Shui-Cheng Lee; Meng-Lun Liu; Jing-Ying Lee; Wen-Ming Wang; Chia-Chi Wang
Journal:  J Biomed Sci       Date:  2010-07-15       Impact factor: 8.410

8.  Analytical and clinical validation of the 25 OH vitamin D assay for the LIAISON automated analyzer.

Authors:  Diana L Ersfeld; D Sudhaker Rao; Jean-Jacques Body; James L Sackrison; Andrew B Miller; Nayana Parikh; Tar Lisha Eskridge; Amy Polinske; Gregory T Olson; Gordon D MacFarlane
Journal:  Clin Biochem       Date:  2004-10       Impact factor: 3.281

Review 9.  Vitamin D status: measurement, interpretation, and clinical application.

Authors:  Michael F Holick
Journal:  Ann Epidemiol       Date:  2008-03-10       Impact factor: 3.797

10.  A ChIP-seq defined genome-wide map of vitamin D receptor binding: associations with disease and evolution.

Authors:  Sreeram V Ramagopalan; Andreas Heger; Antonio J Berlanga; Narelle J Maugeri; Matthew R Lincoln; Amy Burrell; Lahiru Handunnetthi; Adam E Handel; Giulio Disanto; Sarah-Michelle Orton; Corey T Watson; Julia M Morahan; Gavin Giovannoni; Chris P Ponting; George C Ebers; Julian C Knight
Journal:  Genome Res       Date:  2010-08-24       Impact factor: 9.043

View more
  7 in total

Review 1.  Association between serum vitamin D and severity of liver fibrosis in chronic hepatitis C patients: a systematic meta-analysis.

Authors:  Yue-qiu Luo; Xiao-xing Wu; Zong-xin Ling; Yi-wen Cheng; Li Yuan; Charlie Xiang
Journal:  J Zhejiang Univ Sci B       Date:  2014-10       Impact factor: 3.066

2.  Serum vitamin D₃ does not correlate with liver fibrosis in chronic hepatitis C.

Authors:  Yan Ren; Mei Liu; Jing Zhao; Feng Ren; Yu Chen; Jun-Feng Li; Jing-Yun Zhang; Feng Qu; Jin-Lan Zhang; Zhong-Ping Duan; Su-Jun Zheng
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

3.  Vitamin D status, liver enzymes, and incident liver disease and mortality: a general population study.

Authors:  Tea Skaaby; Lise Lotte Nystrup Husemoen; Anders Borglykke; Torben Jørgensen; Betina Heinsbæk Thuesen; Charlotta Pisinger; Lars Ebbe Schmidt; Allan Linneberg
Journal:  Endocrine       Date:  2013-11-23       Impact factor: 3.633

4.  25-Vitamin D levels in chronic hepatitis C infection: association with cirrhosis and sustained virologic response.

Authors:  David Backstedt; Mark Pedersen; Myunghan Choi; Anil Seetharam
Journal:  Ann Gastroenterol       Date:  2017-01-05

5.  Vitamin D-related gene polymorphism predict treatment response to pegylated interferon-based therapy in Thai chronic hepatitis C patients.

Authors:  Kessarin Thanapirom; Sirinporn Suksawatamnuay; Wattana Sukeepaisarnjaroen; Pisit Tangkijvanich; Sombat Treeprasertsuk; Panarat Thaimai; Rujipat Wasitthankasem; Yong Poovorawan; Piyawat Komolmit
Journal:  BMC Gastroenterol       Date:  2017-04-17       Impact factor: 3.067

6.  Association Between Vitamin D Levels and Treatment Response to Direct-Acting Antivirals in Chronic Hepatitis C: A Real-World Study.

Authors:  Vijay Gayam; Amrendra Kumar Mandal; Mazin Khalid; Osama Mukhtar; Arshpal Gill; Pavani Garlapati; Benjamin Tiongson; Jagannath Sherigar; Mohammed Mansour; Smruti Mohanty
Journal:  Gastroenterology Res       Date:  2018-02-08

7.  Vitamin D Deficiency as an Important Biomarker for the Increased Risk of Coronavirus (COVID-19) in People From Black and Asian Ethnic Minority Groups.

Authors:  Shahina Pardhan; Lee Smith; Raju P Sapkota
Journal:  Front Public Health       Date:  2021-01-22
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.